No Data
Express News | Insilico Medicine -Series E Financing Led by a Private Equity Fund of Value Partners Group
Insilico Medicine Secures $110 Million Series E Financing to Advance AI-Driven Drug Discovery Innovation
Value Partners Group Announces Final Dividend for 2024
VALUE PARTNERS (00806) will distribute a final dividend of HKD 0.01 per share on May 30.
VALUE PARTNERS (00806) announced that it will distribute dividends on May 30, 2025, based on the record as of December 3, 2024...
VALUE PARTNERS (00806.HK) appointed Lee Wai Hung as an independent non-executive Director.
On March 13, Glorious Group announced that Mr. Till Rosar has submitted his resignation as an independent non-executive director, as well as a member of the Audit Committee, Nomination Committee, and Remuneration Committee, due to his desire to develop personal business interests. The Board of Directors is pleased to announce that Mr. Li Weihong has been appointed as an independent non-executive director and as a member of the Audit Committee, Nomination Committee, and Remuneration Committee, effective from March 13, 2025.
Value Partners Group Reports 2024 Financial Results With Increased Investment Gains
